S'abonner

Modification effects of SanWei GanJiang Powder on liver and intestinal damage through reversing bile acid homeostasis - 16/06/19

Doi : 10.1016/j.biopha.2019.109044 
Na Li a, 1, Bijun Wang a, 1, Yuhuan Wu a, Xia Luo a, Zhengyuan Chen a, Chuanlan Sang b, , Tianqin Xiong a,
a Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, No. 232 Outer Ring Road, Guangzhou, Guangdong, 510006, China 
b Laboratory of Experimental Animal, Guangzhou University of Chinese Medicine, No. 12 Airport Road, Guangzhou, Guangdong, 510405, China 

Corresponding author at: Laboratory of Experimental Animal, Guangzhou University of Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou, Guangdong, China.Laboratory of Experimental AnimalGuangzhou University of Chinese MedicineNo. 12 Airport RoadBaiyun DistrictGuangzhouGuangdongChina⁎⁎Corresponding author at: Room A517, Pharmaceutical Building, Guangzhou University of Chinese Medicine, No. 232 Outer Ring Road, Panyu District, Guangzhou, Guangdong, China.Guangzhou University of Chinese MedicineRoom A517Pharmaceutical BuildingNo. 232 Outer Ring RoadPanyu DistrictGuangzhouGuangdongChina

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages 12
Iconographies 9
Vidéos 0
Autres 0

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Abstract

Background

Sanwei Ganjiang Powder (SWGJ), derived from traditional Chinese medicine (TCM), has long demonstrated its effectiveness in long-term liver damage therapy. Recent studies indicated that it can also regulate the intestinal tract, although the underlying molecular mechanisms of this remain mysterious. The aim of the study is to investigate the mechanisms of SWGJ against dysbacteriosis and carbon tetrachloride (CCl4)-induced gut-liver axis damage underlying bile acid enterohepatic circulation.

Methods

To observe the regulatory effects of SWGJ on Liver and Intestinal Damage, we explored two animal models. In model 1, sixty BALB/c mice were subjected to oral gavage with 12 g/kg of ceftriaxone sodium for 10d; during this time, SWGJ, bifendate and bifico were sequentially administered over 7d. In model 2, the model of chronic liver injury was induced by subcutaneous injection of 40% CCl4 oil solution twice per week for 8 weeks. From the 3rd week, SWGJ, bifendate and bifico were sequentially administered for 6 weeks. Intestinal flora (16S rDNA analysis), histology (H&E staining), tight connections (Immunohistochemistry, IHC), ultrastructure (Transmission electron microscopy, TEM), inflammatory cytokines and LPS (Enzyme-linked immunosorbent assay, ELISA) of the intestines were assessed, and liver function was also evaluated by methods including ALT, AST and H&E staining. The levels of protein associated with bile acid metabolism were assessed by western blot.

Results

In model 1, SWGJ significantly decreased the activity of inflammatory cytokines and LPS compared with the ceftriaxone sodium group. In addition, SWGJ improved symptoms of intestinal flora imbalance; further, ZO-1 and occludin in the cytoplasm of intestinal villus epithelial cells was increased, and the histopathology of the ileum was improved. Notably, the expression of ALT and AST was significant increased, and disordered hepatic lobule structures were clearly observed in liver histopathology in model group; SWGJ can significantly improve these changes. Furthermore, the levels of proteins related to bile acid synthesis, such as CYP7A1, were significantly upregulated in the SWGJ group compared with the model, and proteins related to excretion and reabsorption, such as NTCP, Mrp2 and BESP, were also upregulated. Importantly, SWGJ increased the nuclear expression of nuclear factor-E2-related factor-2 (Nrf2). Similar results appeared in model 2.

Conclusion

This study suggests that SWGJ may elicit significant effects on the treatment of gut-liver axis damage, potential mechanisms at least partially involve bile acid enterohepatic, and increasing of the nuclear Nrf2 levels.

Le texte complet de cet article est disponible en PDF.

Keywords : Traditional Chinese medicine, Sanwei Ganjiang Powder, Gut microbiota, Gut-liver axis, Bile acid enterohepatic circulation, Nuclear factor-E2-related factor-2


Plan


© 2019  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 116

Article 109044- août 2019 Retour au numéro
Article précédent Article précédent
  • Baicalin regulates depression behavior in mice exposed to chronic mild stress via the Rac/LIMK/cofilin pathway
  • Ye Lu, Guoqiang Sun, Fan Yang, Zhenwei Guan, Zui Zhang, Jing Zhao, Yongyong Liu, Li Chu, Lin Pei
| Article suivant Article suivant
  • Candesartan attenuates hypertension-associated pathophysiological alterations in the gut
  • Dandan Wu, Xiaoting Tang, Liliqiang Ding, Jingang Cui, Peiwei Wang, Xiaoye Du, Jianyun Yin, Wenjian Wang, Yu Chen, Teng Zhang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.